Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02337387 · ClinicalTrials.gov registry record · Phase 1
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02337387 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 28 participants.
The verdict
NCT02337387, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the tolerability of two different formulations of blosozumab in women who have reached menopause. This study will last approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to starting the study.
Interventions
- OTHER Placebo
- BIOLOGICAL Blosozumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02337387
The ClinicalTrials.gov registry entry for NCT02337387 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02337387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02337387 about?
NCT02337387 is a clinical study titled "A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women". The purpose of this study is to evaluate the tolerability of two different formulations of blosozumab in women who have reached menopause. This study will last approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to starting the study.
What is the current status of trial NCT02337387?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2015-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02337387?
The interventions under investigation include: Placebo (OTHER), Blosozumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02337387?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.